| 'Intra-luminal radiofrequency ablation (Habib EndoHPB) | Non applicable | National Taiwan University Hospital | Traitement symptomatique | | À vérifier |
| "3-Hole" subxiphorid and subcostal approach | Phase 2 | Tang-Du Hospital | À vérifier | China | À vérifier |
| "Longitudinal Analysis of Amylin Levels in Migraine Patients Undergoing an Anti- CGRP/CGRPr Treatment" | À vérifier | Fundación Marques de Valdecilla | À vérifier | | À vérifier |
| (-)-Epicatechin | Phase 2 | Craig McDonald, MD | À vérifier | United States | À vérifier |
| (BCRL) — The Effect of Self-Management Interventions Among Patients With Breast Cancer Related-Lymphedema | Non applicable | Al-Zaytoonah University of Jordan | Traitement symptomatique | Jordan | À vérifier |
| [ 18F]3F4AP | Phase 1 | Yale University | À vérifier | United States | À vérifier |
| [11C]-CS1P1 | À vérifier | Tammie L. S. Benzinger, MD, PhD | Immunomodulation | United States | À vérifier |
| [11C]CPPC PET ligand | Phase 1/2 | Johns Hopkins University | À vérifier | | À vérifier |
| [11C]MODAG-005 | Phase 1 | MODAG GmbH | À vérifier | Germany | À vérifier |
| [11C]PIB | Phase 1 | Yale University | À vérifier | United States | À vérifier |
| [18F] AV-133 PET Imaging | Phase 2 | Michael J. Fox Foundation for Parkinson's Research | Ralentissement de la progression | United States | À vérifier |
| [18F] FZTA | À vérifier | Washington University School of Medicine | Immunomodulation | United States | À vérifier |
| [18F] MNI-558 | Phase 1 | Institute for Neurodegenerative Disorders | À vérifier | United States | À vérifier |
| [18F]-APN-1607 | Phase 3 | JYAMS PET Research & Development Limited | À vérifier | China | À vérifier |
| [18F]ACI-19626 PET in TDP-43 Proteinopathies | Phase 1 | AC Immune SA | Traitement symptomatique | Netherlands | À vérifier |
| [18F]DPA-714 Positron Emission Tomography Scan | Phase 1 | University of California, Davis | Immunomodulation | United States | À vérifier |
| [18F]Fluorbetazine injection | Phase 3 | HTA Co., Ltd. | À vérifier | China | À vérifier |
| [18F]fluorodeprenyl-D2 | Non applicable | Parc de Salut Mar | Ralentissement de la progression | Spain | À vérifier |
| [18F]FMISO-PET with contrast-enhanced MRI | Phase 1 | University of Alabama at Birmingham | À vérifier | United States | À vérifier |
| [18F]FT8 PET Imaging in Immunoglobulin Light Chain Amyloidosis | À vérifier | Tianjin Medical University | À vérifier | China | À vérifier |
| [18F]MC225 | Phase 1 | University Medical Center Groningen | À vérifier | Netherlands | À vérifier |
| [18F]MK6240 | Phase 1 | Yale University | À vérifier | United States | À vérifier |
| [18F]MNI-792 (tracer) | Phase 1 | Takeda | À vérifier | United States | À vérifier |
| [18F]NIDF PET Imaging in Tau-related Diseases | À vérifier | Tianjin Medical University | À vérifier | China | À vérifier |
| [18F]PBR06 | Phase 1 | Molecular NeuroImaging | | United States | À vérifier |
| [18F]PI-2620 | Phase 3 | Lantheus Biosciences Ltd. | À vérifier | United States | À vérifier |
| [C-11]Methylreboxetine | Phase 1/2 | Brigham and Women's Hospital | Traitement symptomatique | United States | À vérifier |
| [C-11]PBR28 | Phase 1/2 | Brigham and Women's Hospital | Traitement symptomatique | United States | À vérifier |
| [C-11]PiB-PET/MRI | Phase 2 | University of Alabama at Birmingham | À vérifier | United States | À vérifier |
| [F-18]AV-1451-PET | Phase 1 | University of Alabama at Birmingham | À vérifier | United States | À vérifier |
| [F-18]DPA714 administration IV | Phase 1 | University of Alabama at Birmingham | À vérifier | United States | À vérifier |
| [F-18]Fallypride | Phase 3 | Emory University | À vérifier | United States | À vérifier |
| [F-18]PBR06 | Phase 1/2 | Brigham and Women's Hospital | Traitement symptomatique | United States | À vérifier |
| [O-15]-Water PET Myocardial Perfusion Imaging (MPI) | Phase 3 | MedTrace Pharma A/S | À vérifier | United States, Canada, Denmark, Germany, Netherlands, Sweden | À vérifier |
| @HOME — ECOCAPTURE for the Assessment of Apathy Under Real-life Conditions | À vérifier | Institut National de la Santé Et de la Recherche Médicale, France | À vérifier | France | À vérifier |
| •Group A: Patients will receive Medical treatment only: Beta-blockers (Propranolol) , Calcium channel blockers | Non applicable | Sohag University | À vérifier | Egypt | À vérifier |
| 0.2 mL/kg of aminophylline 10 mg/mL [group A2] | Phase 2 | King Faisal University | À vérifier | Saudi Arabia | À vérifier |
| 0.2 mL/kg of aminophylline 15 mg/mL [group A3] | Phase 2 | King Faisal University | À vérifier | Saudi Arabia | À vérifier |
| 0.2 mL/kg of aminophylline 20 mg/mL [group A4] | Phase 2 | King Faisal University | À vérifier | Saudi Arabia | À vérifier |
| 0.2 mL/kg of aminophylline 25 mg/mL [group A5] | Phase 2 | King Faisal University | À vérifier | Saudi Arabia | À vérifier |
| 0.5mg elsunersen | Phase 3 | Praxis Precision Medicines | À vérifier | United States, Brazil, Germany, Italy | À vérifier |
| 0.9% NaCl | Phase 2 | Nelly Pitteloud | Immunomodulation | Switzerland | À vérifier |
| 0.9% sodium chloride | Phase 2/3 | Isfahan University of Medical Sciences | À vérifier | Iran | À vérifier |
| 1 Hypercapnic challenge while participant is awake | Non applicable | Hospices Civils de Lyon | À vérifier | France | À vérifier |
| 1 X 10^6 cells/kg | Phase 1 | Medical College of Wisconsin | Immunomodulation | United States | À vérifier |
| 1-Month DAPT | Non applicable | Ulsan University Hospital | À vérifier | | À vérifier |
| 1-week PBI | Non applicable | Fudan University | À vérifier | China | À vérifier |
| 1.0 × 10^6 cells/kg once every two weeks for a total of 3 doses | Phase 1/2 | GuangZhou Cellgenes Biotechnology Co., Ltd. | À vérifier | China | À vérifier |
| 1.0mg/kg/day PRAX-562 | Phase 3 | Praxis Precision Medicines | À vérifier | United States, Australia, Brazil | À vérifier |
| 1.5mg/kg/day PRAX-562 | Phase 3 | Praxis Precision Medicines | À vérifier | United States, Australia, Brazil | À vérifier |
| 1/2 dose of 99mTc OR 201Tl tracers | Non applicable | Ottawa Heart Institute Research Corporation | À vérifier | Canada | À vérifier |
| 100% Oxygen | Phase 4 | Jay C. Buckey Jr. | À vérifier | | À vérifier |
| 1000mg BAT4306F | Phase 1 | Bio-Thera Solutions | Immunomodulation | China | À vérifier |
| 11C-MC1 | Phase 1 | National Institute of Mental Health (NIMH) | Immunomodulation | United States | À vérifier |
| 11C-Methylreboxetine (11C-MRB) | À vérifier | National Institute of Neurological Disorders and Stroke (NINDS) | Traitement symptomatique | United States | À vérifier |
| 11C-PS13 | Phase 1 | National Institute of Mental Health (NIMH) | Immunomodulation | United States | À vérifier |
| 12 cm2 - 2 Active DMTS Patches | Phase 2 | Teikoku Pharma USA, Inc. | À vérifier | United States | À vérifier |
| 12-month DAPT | Phase 4 | Kindai University | À vérifier | Japan | À vérifier |
| 13-PCV Booster | Phase 3 | Hoffmann-La Roche | | United States, Canada | À vérifier |
| 13N-Ammonia | À vérifier | National Institute of Neurological Disorders and Stroke (NINDS) | Traitement symptomatique | United States | À vérifier |
| 15-0 H20 | À vérifier | National Human Genome Research Institute (NHGRI) | À vérifier | United States | À vérifier |
| 150% of their routine home dopaminergic medications dose right in the clinic | Non applicable | Stardots AB | À vérifier | United States | À vérifier |
| 177Lu-DFC413 | Phase 1 | Novartis Pharmaceuticals | À vérifier | United States, Canada, Denmark, France, Germany, Israel, Singapore | À vérifier |
| 177Lu-DOTA-EB-TATE | Phase 1/2 | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | À vérifier | United States | À vérifier |
| 18F-AV-1451 | Phase 2 | Mayo Clinic | À vérifier | United States | À vérifier |
| 18F-DCFPyL | Phase 2 | National Cancer Institute (NCI) | À vérifier | United States | À vérifier |
| 18F-DOPA | À vérifier | National Institute of Neurological Disorders and Stroke (NINDS) | Traitement symptomatique | United States | À vérifier |
| 18F-Dopamine | À vérifier | National Institute of Neurological Disorders and Stroke (NINDS) | Traitement symptomatique | United States | À vérifier |
| 18F-FDG | À vérifier | Second Affiliated Hospital, School of Medicine, Zhejiang University | À vérifier | China | À vérifier |
| 18F-FDG PET Imaging Analysis of Antiepileptic Drug Response in BECTS | À vérifier | Second Affiliated Hospital, School of Medicine, Zhejiang University | À vérifier | China | À vérifier |
| 18F-florbetaben | Phase 1 | National Institute of Mental Health (NIMH) | Immunomodulation | United States | À vérifier |
| 18F-Florbetaben (FBB) | Phase 2 | Patrick Lao | À vérifier | United States | À vérifier |
| 18F-Flortaucipir radiopharmaceutical | Phase 1 | Tharick Pascoal | À vérifier | United States, Canada, Spain | À vérifier |
| 18F-Fluoro-L-dopa | À vérifier | National Institute of Mental Health (NIMH) | À vérifier | United States | À vérifier |
| 18F-MK-6240 | Phase 2 | NYU Langone Health | Remyélinisation indirecte / réparation | United States | À vérifier |
| 18F-MK-6240 radiopharmaceutical | Phase 1 | Tharick Pascoal | À vérifier | United States, Canada, Spain | À vérifier |
| 18F-MK6240 | Phase 2 | Patrick Lao | À vérifier | United States | À vérifier |
| 18F-PF974 | Phase 1 | National Institute of Mental Health (NIMH) | Immunomodulation | United States | À vérifier |
| 18F-rhPSMA-7.3 | Phase 2 | Washington University School of Medicine | À vérifier | United States | À vérifier |
| 1mg elsunersen | Phase 3 | Praxis Precision Medicines | À vérifier | United States, Brazil, Germany, Italy | À vérifier |
| 1ml of triamcinolone (40mg/1ml) | Phase 3 | University Hospital Plymouth NHS Trust | Traitement symptomatique | United Kingdom | À vérifier |
| 2-hydroxybenzylamine acetate | Phase 1/2 | MTI Biotech Inc | À vérifier | United States | À vérifier |
| 2.0 × 10^6 cells/kg once every two weeks for a total of 3 doses | Phase 1/2 | GuangZhou Cellgenes Biotechnology Co., Ltd. | À vérifier | China | À vérifier |
| 2.5 X 10^6 cells/kg | Phase 1 | Medical College of Wisconsin | Immunomodulation | United States | À vérifier |
| 20 mg/day vormatrogine for 12 weeks | Phase 3 | Praxis Precision Medicines | À vérifier | United States | À vérifier |
| 23-PPV | Phase 3 | Hoffmann-La Roche | | United States, Canada | À vérifier |
| 26G Needle | Non applicable | Medipol University | Traitement symptomatique | Turkey (Türkiye) | À vérifier |
| 270mg Idebenone | Phase 3 | Second Affiliated Hospital, Zhejiang University, School of Medicine | À vérifier | China | À vérifier |
| 3 Year Follow up on ANO5 Patients | À vérifier | Rigshospitalet, Denmark | Ralentissement de la progression | Denmark | À vérifier |
| 3-week PBI | Non applicable | Fudan University | À vérifier | China | À vérifier |
| 3, 4-Diaminopyridine | À vérifier | University of Colorado, Denver | À vérifier | United States | À vérifier |
| 3.0 × 10^6 cells/kg once every two weeks for a total of 3 doses | Phase 1/2 | GuangZhou Cellgenes Biotechnology Co., Ltd. | À vérifier | China | À vérifier |
| 30 Gauge Needle | Non applicable | Medipol University | Traitement symptomatique | Turkey (Türkiye) | À vérifier |
| 30 mg/day vormatrogine for 12 weeks | Phase 3 | Praxis Precision Medicines | À vérifier | United States | À vérifier |
| 3d printed Stabilization splint | Non applicable | Postgraduate Institute of Dental Sciences Rohtak | Traitement symptomatique | India | À vérifier |
| 3D-printed coplanar template | NA | Ruijin Hospital | À vérifier | China | À vérifier |
| 3D-printed non-coplanar template | NA | Ruijin Hospital | À vérifier | China | À vérifier |
| 3K3A-APC Protein | Phase 2 | Macquarie University, Australia | À vérifier | Australia | À vérifier |
| 3T Magnetic Resonance Imaging (MRI) | À vérifier | University of Pennsylvania | À vérifier | United States | À vérifier |
| 4°C saline infusion | Non applicable | Guangdong Second Provincial General Hospital | À vérifier | China | À vérifier |
| 40 Hz Synchronous Audio-Visual Stimulation | Non applicable | The First Affiliated Hospital of Xiamen University | Traitement symptomatique | China | À vérifier |
| 40 mg/day vormatrogine for 12 weeks | Phase 3 | Praxis Precision Medicines | À vérifier | United States | À vérifier |
| 5-Fluorouracil | Phase 3 | Incyte Corporation | À vérifier | United States, Australia, Austria, Canada, Hungary, Italy, Japan, Poland, … | À vérifier |
| 5-Fluorouracil (5-FU) | Phase 1/2 | Merck Sharp & Dohme LLC | À vérifier | United States, Brazil, Chile, China, France, Germany, Italy, Norway, … | À vérifier |
| 5-FU | Phase 3 | Merck Sharp & Dohme LLC | Ralentissement de la progression | United States, Argentina, Belgium, Brazil, Canada, Chile, China, Czechia, … | À vérifier |
| 5-HT RBD REM Sleep Behavior Disorder | Non applicable | University of Minnesota | À vérifier | United States | À vérifier |
| 5-hydroxytryptamine subtype 3 receptor antagonist | Phase 2 | Merck Sharp & Dohme LLC | Immunomodulation | United States, Chile, Germany, Greece, Hungary, Israel, Italy, Poland, … | À vérifier |
| 5-year Follow-up DPA-714-PET/MRI | Phase 1/2 | University of Alabama at Birmingham | Immunomodulation + Remyélinisation indirecte / réparation | United States | À vérifier |
| 5% 5-fluorouracil Topical Cream | Phase 2 | UNC Lineberger Comprehensive Cancer Center | À vérifier | Kenya | À vérifier |
| 5% lidocaine/5 mg/ml 0.02% estradiol compound cream | Phase 2 | Duke University | Traitement symptomatique | United States | À vérifier |
| 50 mg Usnoflast | Phase 2 | Zydus Therapeutics Inc. | À vérifier | United States, Australia, Belgium, Canada, France, Germany, Ireland, Italy, … | À vérifier |
| 500mg BAT4306F | Phase 1 | Bio-Thera Solutions | Immunomodulation | China | À vérifier |
| 5G-Enabled Remote Robotic-Assisted Bronchoscopy-Guided Cryoablation | Non applicable | Shanghai Chest Hospital | À vérifier | China | À vérifier |
| 6-Month DAPT | Non applicable | Ulsan University Hospital | À vérifier | | À vérifier |
| 60 MHz HD-IVUS-guided PCI | Non applicable | Harbin Medical University | Traitement symptomatique | China | À vérifier |
| 64-channel EEG | À vérifier | Norwegian University of Science and Technology | À vérifier | Norway | À vérifier |
| 68-Gallium DOTATATE | Phase 2 | National Cancer Institute (NCI) | Traitement symptomatique | United States | À vérifier |
| 68Ga-NNS309 | Phase 1 | Novartis Pharmaceuticals | À vérifier | United States, Canada, Denmark, France, Germany, Israel, Singapore | À vérifier |
| 68Ga-P16-093 | Phase 2 | First Affiliated Hospital of Fujian Medical University | À vérifier | China | À vérifier |
| 75 mg Usnoflast | Phase 2 | Zydus Therapeutics Inc. | À vérifier | United States, Australia, Belgium, Canada, France, Germany, Ireland, Italy, … | À vérifier |
| 750mg BAT4306F | Phase 1 | Bio-Thera Solutions | Immunomodulation | China | À vérifier |
| 7T MRI | À vérifier | Norwegian University of Science and Technology | À vérifier | Norway | À vérifier |
| 80-ppm NO | Phase 1/2 | Tomsk National Research Medical Center of the Russian Academy of Sciences | À vérifier | Russia | À vérifier |
| 810 nm laser acupuncture | Non applicable | Taichung Veterans General Hospital | Traitement symptomatique | Taiwan | À vérifier |
| 900mg BAT4306F | Phase 1 | Bio-Thera Solutions | Immunomodulation | China | À vérifier |
| 90mg Idebenone | Phase 3 | Second Affiliated Hospital, Zhejiang University, School of Medicine | À vérifier | China | À vérifier |
| a blood withdrawal will be obtained | À vérifier | IRCCS San Raffaele | À vérifier | Italy | À vérifier |
| A Canadian Study Assessing the Utility of the Treatment Optimization Recommendations in Multiple Sclerosis | À vérifier | Merck KGaA, Darmstadt, Germany | Ralentissement de la progression | | À vérifier |
| A Clinical Trial to Evaluate the Effects of Peptide Gummies on Markers of Inflammation, Physical Performance, and Recovery | Non applicable | Parlay Wellness | Immunomodulation | United States | À vérifier |
| A Clinical Trial to Investigate the Safety and Efficacy of Papillex® on Abnormal Cervical Cells Caused by HPV. | NA | Papillex Inc. | À vérifier | Canada | À vérifier |
| A Collaborative Palliative and Leukemia Care Model for Patients With AML and MDS Receiving Non-Intensive Therapy | NA | Massachusetts General Hospital | Traitement symptomatique | United States | À vérifier |
| A Ketogenic Diet Acts on Cortical But Not Subcortical Responsivity in Migraineurs | NA | University of Roma La Sapienza | Traitement symptomatique | Italy | À vérifier |
| A Multicenter Study to Evaluate Next-Generation Sequencing (NGS) Testing and Monitoring of B-Cell Recovery to Guide Management Following Chimeric Antigen Receptor T-cell (CART) Ind | Non applicable | National Cancer Institute (NCI) | Thérapie cellulaire | United States | À vérifier |
| A Multifaceted Assessment of Eating Behaviors, Anthropometric Measurements and Body Composition in Pediatric Patients With Drug-resistant Epilepsy on a Ketogenic Diet and Healthy C | À vérifier | Wroclaw Medical University | À vérifier | Poland | À vérifier |
| A Multiple Dose Study to Investigate Safety, Tolerability and Pharmacokinetics of TBN | Phase 1 | Guangzhou Magpie Pharmaceuticals Co., Ltd. | À vérifier | | À vérifier |
| A Natural History Study of Patients With GNE Myopathy and GNE-Related Diseases | À vérifier | National Human Genome Research Institute (NHGRI) | Traitement symptomatique | United States | À vérifier |
| A Natural History Study of RYR1-Related Disorders | À vérifier | National Institutes of Health Clinical Center (CC) | Traitement symptomatique | United States | À vérifier |
| A Natural History Study Seeks to Understand the Clinical, Genomic, Pharmacological, Laboratory, and Dietary Determinates of Pyrimidine and Purine Metabolism Disorders | À vérifier | National Human Genome Research Institute (NHGRI) | Traitement symptomatique | United States | À vérifier |
| A Novel Rural Integrated Care and Early Prevention Model for Older Adults at High Risk of or Living With Stroke in China | Non applicable | Jiangsu Province (Suqian) Hospital | À vérifier | China | À vérifier |
| A Patient-tailored Genetic/Biomarker/iPSC Combined Approach in ALS - PERMEALS | À vérifier | A.O.U. Città della Salute e della Scienza | Thérapie cellulaire + Neuroprotection + Ralentissement de la progression | Italy | À vérifier |
| A Post Authorization Registry Study of Participants Treated With LEQEMBI | À vérifier | Eisai Limited | Ralentissement de la progression | Canada | À vérifier |
| A Prospective Nurse Cohort Study in Xiamen, China | À vérifier | The First Affiliated Hospital of Xiamen University | Ralentissement de la progression | China | À vérifier |
| A Reeducation Program to Effort to Improve the Walking of Multiple Sclerosis Patients | NA | Lille Catholic University | Traitement symptomatique | France | À vérifier |
| A Self-management Based Survivorship Intervention for Chinese Cancer Survivors | Non applicable | The University of Hong Kong | Traitement symptomatique | Hong Kong | À vérifier |
| A Study Comparing Effectiveness of Kesimpta® (Ofatumumab) Versus Ocrevus® (Ocrelizumab) in Real-world Practice | À vérifier | Novartis Pharmaceuticals | À vérifier | United States | À vérifier |
| A Study of Brain Aging in Vietnam War Veterans | À vérifier | University of Southern California | Traitement symptomatique | United States | À vérifier |
| A Study of Treatment Patterns and Annualized Relapse Rate in Multiple Sclerosis Patients Who Escalate Versus Continue Disease-Modifying Therapies Following Relapse | À vérifier | Novartis Pharmaceuticals | À vérifier | United States | À vérifier |
| A Study of Wearable Devices to Predict Migraines | Non applicable | Mayo Clinic | À vérifier | United States | À vérifier |
| A Study to Assess New Participant's Perspectives Beyond Clinical Efficacy of Monoclonal Antibody-Based Relapsing Remitting Multiple Sclerosis (RRMS) Treatments | À vérifier | Biogen | Traitement symptomatique | United States | À vérifier |
| A Study to Evaluate the Incidence of Clinically Suspicious Lambert-Eaton Myasthenic Syndrome (LEMS) in Subjects Diagnosed With Small Cell Lung Cancer (SCLC) | À vérifier | Addario Lung Cancer Medical Institute | Traitement symptomatique | United States | À vérifier |